Dynavax Technologies Corp... (DVAX)
13.33
0.24 (1.83%)
At close: Feb 20, 2025, 3:59 PM
12.33
-7.49%
After-hours: Feb 20, 2025, 04:57 PM EST
undefined% (undefined)
| Bid | 12.3 |
| Market Cap | 1.75B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.15 |
| PE Ratio (ttm) | 88.87 |
| Forward PE | n/a |
| Analyst | Sell |
| Ask | 13.59 |
| Volume | 1,434,116 |
| Avg. Volume (20D) | 1,647,983 |
| Open | 13.02 |
| Previous Close | 13.09 |
| Day's Range | 13.02 - 13.35 |
| 52-Week Range | 9.74 - 13.89 |
| Beta | undefined |
About DVAX
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a coll...
Sector Healthcare
IPO Date Feb 19, 2004
Employees 408
Stock Exchange NASDAQ
Ticker Symbol DVAX
Website https://www.dynavax.com
Analyst Forecast
According to 2 analyst ratings, the average rating for DVAX stock is "Sell." The 12-month stock price forecast is $21.5, which is an increase of 61.29% from the latest price.
Buy 50.00%
Hold 0.00%
Sell 50.00%
Next Earnings Release
Dynavax Technologies Corporation is scheduled to release its earnings on Feb 20, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-3.79%
Dynavax shares are trading lower after Goldman Sac...
Unlock content with
Pro Subscription
3 months ago
+8.24%
Dynavax Technologies shares are trading higher after the company reported better-than-expected Q3 EPS results and launched a $200 million share buyback program. HC Wainwright & Co. reiterated a Buy rating on the stock.
